Analysts Expect Qiagen (NASDAQ:QGEN) Will Post Earnings of $0.45 Per Share

Equities research analysts expect that Qiagen (NASDAQ:QGENGet Rating) will post earnings of $0.45 per share for the current quarter, according to Zacks. Three analysts have issued estimates for Qiagen’s earnings. The highest EPS estimate is $0.49 and the lowest is $0.44. Qiagen posted earnings of $0.67 per share during the same quarter last year, which would indicate a negative year over year growth rate of 32.8%. The firm is scheduled to report its next earnings results on Monday, January 1st.

On average, analysts expect that Qiagen will report full-year earnings of $2.10 per share for the current fiscal year, with EPS estimates ranging from $2.05 to $2.22. For the next year, analysts expect that the company will report earnings of $2.16 per share, with EPS estimates ranging from $2.08 to $2.23. Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Qiagen.

Separately, StockNews.com started coverage on Qiagen in a report on Thursday, March 31st. They issued a “strong-buy” rating on the stock.

Shares of NASDAQ QGEN traded up $1.76 during midday trading on Friday, hitting $47.39. The company’s stock had a trading volume of 746,021 shares, compared to its average volume of 787,450. The company has a current ratio of 2.19, a quick ratio of 1.85 and a debt-to-equity ratio of 0.46. The business’s 50 day moving average price is $46.84. Qiagen has a 12-month low of $41.32 and a 12-month high of $58.00. The firm has a market capitalization of $10.76 billion, a price-to-earnings ratio of 20.43, a P/E/G ratio of 1.59 and a beta of 0.33.

About Qiagen (Get Rating)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

Recommended Stories

Get a free copy of the Zacks research report on Qiagen (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.